Lyophilization is basically a freeze-drying process that removes water from a product after it is frozen and placed under a vacuum, producing a soft powder, sometimes referred to as a cake. If we take that process and apply it to a single droplet of liquid, we are creating a lyo ‘bead’ rather than a lyo ‘cake’.
Lyobeads are an excellent alternative to the traditional cakes because they:
Copyright © 2022 ATS Life Sciences. All rights reserved.
Life Sciences
B L O G P O S T
Author: Brandon Cole, P.Eng. Business Development and Strategic Planning Manager, ATS Life Sciences
Published on: Thursday, July 7, 2022
About ATS Life Sciences
ATS Life Sciences provides high-quality, high-value automation solutions to manufacturers of medical technology and pharmaceutical products where regulatory compliance is critical. We are dedicated to assisting our customers in improving quality of life for people around the world. ATS Life Sciences is a division of ATS Automation, an industry-leading automation solutions provider to many of the world’s most successful companies.
The relatively high cost of lyobead formation (because of the highly specialized equipment) can be a barrier to making this part of your in-house process. You’ll need some initial process development for your therapeutic using this process to learn what works best, but we already know that not all vaccines and reagents can be lyophilized.
Additional development time (12-24 months) is often required as there is a high upfront development cost with respect to excipient or buffer selection and process definition.
While there is a deep history of freeze drying, the bead form factor is less understood and is an emerging area of specialized knowledge. Closely related are the critical to quality attributes and the associated inspection requirements. These will need to be customized to your specific product and may require a specialty partner for lyobead creation and vision capabilities.
It all starts with a high-resolution pump and specifically-sized dispensing tip which allows us to generate volumes of 2 µL to 30 µL as a single drop with high volume precision. Choose a pump that is scalable for R&D to production environments.
Depending on how you’ll be using the beads, production can be customized to change the shape of the bead, add colour, and adjust size anywhere from 700 nanoliters to 200 microliters, theoretically. Experiment with the dispensing and freezing method to result in the optimal bead for your application.
Depending on the dispensing method the resulting bead could be round from just a nitrogen bath near the dispense tip to asymmetrical if a cryogenic plate is used.
Once the droplet is frozen it is then lyophilized by the batch using a system designed specifically for sublimation and pulling the ice crystals out of the bead. What remains is just the ‘cake’ in multiple bead form which requires handling with care since beads are typically friable and begin to decay under high humidity.
Now that the beads are formed they need to be singulated from the batch and processed into their primary packaging or directly into a diagnostic cartridge, for example. The handling might be done in an isolator using aseptic robotics or in a humidity-controlled environment if it is simply a diagnostic reagent. Depending on the production rate, the picking mechanism may be a simple, single quill or a specially-designed array of quills to place multiple beads at once.
To learn more about the potential for lyophilization in your process, feel free to reach out directly at bcole@atsautomation.com and visit our website to explore the breadth of our life sciences capabilities https://www.atslifesciences.com
Spray drying using high heat does have the advantages of lower equipment costs and shorter turnaround times but also introduces risk in certain applications. API damage can result from air drying complex formulations in a short period of time, when the short dry cycle will not sufficiently remove the moisture, risking degradation.
The shelf life for air-dried products may not be as long as lyophilized products, resulting in an increased risk of wastage.
Currently, approximately 80% of lyophilization happens in vials resulting in
cakes, but beads offer distinct advantages. Beads are easier to inspect during manufacturing. The volume to surface area is high which allows for more rapid reconstitution, meaning more flexibility in the field. In therapeutics, beads can be reconstituted to the required dose on demand (the health care provider can prepare one dose or many), resulting in less waste. In terms of diagnostics, this means less of the sample will be required to mix with the reagent to obtain a result.
Forecasts suggest more than half of injectable drugs will require lyophilization. Lyobeads have a higher barrier for replication because of the special equipment and the excipients required to make the beads work, which gives first movers a big advantage before generic replication cuts into profitability.
Lyophilization has existed for many years as a method for making drug therapies more stable and long-lasting. Now, lyobeads offer more versatility that allows you to experiment with dosing and packaging, reducing the weight and volume of samples, opening up opportunities for innovation.
Beyond the immediate benefits to manufacturers, this new technology also secures supply chains with shelf-stable and transportable products that can be accessed by patients all over the world regardless of the infrastructure available. This technology will open doors to further advancements in patient care and the production of pharmaceuticals.